News
MVdeltaC, a new therapeutic vaccine, demonstrates promising preclinical immuno-oncolytic activities (Abstract)
Read more
Oncovita presents preclinical data on its promising MVdeltaC oncolytic vaccine at SITC Annual Meeting 2022, Nov 8.
Read more
Oncovita presents data of MVdeltaC at Société Française d’Immunothérapie du Cancer (FITC), Institut Curie, Paris, 11 octobre 2022
Read more